<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03175887</url>
  </required_header>
  <id_info>
    <org_study_id>D17107</org_study_id>
    <nct_id>NCT03175887</nct_id>
  </id_info>
  <brief_title>Investigational TMS Treatment for Depression</brief_title>
  <official_title>Dorsolateral Versus Medial Prefrontal TMS for Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>White River Junction Veterans Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>White River Junction Veterans Affairs Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed to help us learn about the effects of Transcranial Magnetic Stimulation&#xD;
      at the forehead versus the left side of the head for treatment of Treatment Resistant&#xD;
      Depression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While transcranial magnetic stimulation (TMS) to the left dorsolateral prefrontal cortex&#xD;
      (DLPFC) is an FDA approved treatment for depression, a growing and converging database&#xD;
      suggests the medial prefrontal cortex (MPFC) may be even more critical to the neurobiology of&#xD;
      depression and antidepressant treatment response. This study will compare the efficacy of&#xD;
      high frequency transcranial madntic stimulation on these two sections of the brain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI's discretion due to needing to modify study protocol.&#xD;
  </why_stopped>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depressive symptoms measured by the 17-item Hamilton Depression Rating Scale</measure>
    <time_frame>Change from baseline Hamilton-17 score to follow-up visit at 1 week after final TMS intervention.</time_frame>
    <description>Depressive symptoms will be measured by the 17-item Hamilton Depression Rating Scale.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Depression</condition>
  <condition>Treatment Resistant Depression</condition>
  <arm_group>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive TMS. They will be randomized to either the left dorsolateral prefrontal cortex or the medial prefrontal cortex.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>After the experimental arm, if a patient was randomized to the medial prefrontal cortex during the experimental arm and it did not work for them, they have the option of returning for a session of TMS to the FDA-approved dorsolateral prefrontal cortex.&#xD;
If they were assigned to the dorsolateral prefrontal cortex, they are not eligible to return for another set of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TMS</intervention_name>
    <description>Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression.</description>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  21-70 years old&#xD;
&#xD;
          -  inadequate response to one current antidepressant medication&#xD;
&#xD;
          -  currently depressed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  psychiatric comorbidities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>White River Junction VA Medical Center</name>
      <address>
        <city>White River Junction</city>
        <state>Vermont</state>
        <zip>05009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 3, 2017</study_first_submitted>
  <study_first_submitted_qc>June 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>White River Junction Veterans Affairs Medical Center</investigator_affiliation>
    <investigator_full_name>Paul Holtzheimer</investigator_full_name>
    <investigator_title>Director of Mood Disorder Services</investigator_title>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>trd</keyword>
  <keyword>treatment-resistant depression</keyword>
  <keyword>TMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

